Zenith Drugs Ltd. · NSE:ZENITHDRUG
Zenith Drugs — Investor Presentation (March 2025)
29 slides from Zenith Drugs's investor presentation, March 2025
Slide 1: Investor Presentation
ZENITH CONTRIBUTINGFOR HEALTH AND WELL BEING Investor Presentation
Slide 2: Disclaimer
Disclaimer The content within this presentation serves the purpose of offering a broad overview of Zenith Drugs Limited and its operations. They should not be construed as investment advice. Independent professional guidance is recommended for individuals with specific investment objectives, financi
Slide 3: Table of Content
Table of Content 1 2 Industry Overview Company Overview 3 4 Financial Future Prospects Highlights
Slide 4: Zenith Drugs: Key Highlights
Zenith Drugs: Key Highlights Pharmaceutical Manufacturing and Trading Company 20+ INR Zenith Drugs is a well established company specialized in manufacturing affordable Years 114.5 Cr. medicines, offering ORS Powder, Liquid Orals, Ointments, Liquid Externals, and Capsules History Revenue in FY2022-2
Slide 5: Industry Overview
INDUSTRY OVERVIEW
Slide 6: Industry Dynamics
Industry Dynamics India's pharma sector enroute to 13% of global Exports: market: Indian pharmaceutical sector supplies Pharmaceutical exports reached US$ 25.3 Bn over 50% of global demand for various in FY23, constituting 6.47% of total exports. vaccines, 40% of generic demand in the US and 25% of
Slide 7: Catalysts behind this growth
Catalysts behind this growth Growing Healthcare Insurance: India's Pharma Impact: India, a global generics leader, with the second-highest FDA- approved Rising healthcare insurance demand in India, fueled by increasing plants, anticipates 120 drugs going off-patent. Expected revenues from medical co
Slide 8: Company Overview
A SA COIMIPANY OVERVIEW
Slide 9: About Zenith Drugs Limited
About Zenith Drugs Limited Established in 2000, Zenith Drugs is a premier pharmaceutical manufacturing and trading company located in Indore. Specializing in a diverse range of products, including branded, generic, and over-the-counter (OTC) items. Zenith Drugs Limited stands as the first pharmaceut
Slide 10: Impressive journey so far
Impressive journey so far Started as a manufacturing Received WHO GMP ISO & compliance Turnover crossed INR 114.5 Cr house for oral and external certification certification Converted into public limited formulations entity 2001 2016 2021 2023 2000 2007 2020 2022 2024 Incorporation of the Started Tur
Slide 11: Inspired by founders' extensive industry experience
Inspired by founders’ extensive industry experienceMr. Sandeep Bhardwaj, Promoter & Managing Director Technical Taskmaster with 2+ decades in pharmaceutical Mr. Anil Malik , (Non-Executive Director) business management, guiding Zenith in qualitative, cost- Bringing 43 years of rich experience in Emp
Slide 12: End-to-end value chain: Crafting excellence from sourcing to delivery
End-to-end value chain: Crafting excellence from sourcing to delivery 1 2 3 4 5 Initiates with sourcing Sourcing excipients like Bulk sourcing of Study of stability, efficacy, taste, Submission for regulatory APIs the binders, fillers, flavors & bottles, caps, labels, and appearance for regulatory a
Slide 13: Product Basket
Product Basket Powder (22% Of Revenue) Liquids (44% Of Solids (9 % Of Revenue) Semi-Solids (25 % Of Revenue) Revenue) Liquid Oral Capsules Liquid syrup Convenient oral providing a reliable dosage forms for ORS source of essential Ointment & Creams accurate & essential A vital electrolyte Specialized
Slide 14: State-of-the-art manufacturing facility
State-of-the-art manufacturing facility Zenith's cutting-edge facility in Indore produces over 250 molecules & 780 WHO GMP Certified Plant Our manufacturing facility proudly holds WHO GMP certification, showcasing our commitment to dosage forms. producing high-quality pharmaceuticals. Dedicated unit
Slide 15: Expanding & unlocking opportunities
Expanding & unlocking opportunities Tablets command 70-80% of pharma sales Most consumed drug dosage form as it is convenient, easy to administrate with precise and accurate dosage Started expansion of 50% of civil work is Leveraging robust distribution Estimated 100% revenue manufacturing facility
Slide 16: Formidable entry barrier and supply chain: The Zenith advantage
Formidable entry barrier and supply chain: The Zenith advantage High barrier to entry for other players Stringent regulatory compliance & WHO-GMP certificate, intellectual property, extensive industry expertise, specialized knowledge and strong distribution network is required Strategic alliances wi
Slide 17: Revenue Segments
Revenue Segments State Wise Sales Segment Wise Sales Product Wise Sales Madhya Pradesh Maharashtra Sale Under Own Brand White Label Manufacturing ORS Powder Liquid Orals Ointments Rajasthan Others Sales to Government Others Liquid Capsules Karnataka Externals • Madhya Pradesh leads with 24%, reflect
Slide 18: Commanding a domestic and global presence
Commanding a domestic and global presence • Strong Presence in 18+ States India • Madhya Pradesh contributes up to 24% in revenue • Strategically located at the center of India making supply chain Rajasthan faster and efficient • Strengthening our position in India through market diversification, Ma
Slide 19: Creating excellence through holistic innovation
Creating excellence through holistic innovation Technology Driven Approach Innovation Culture Focused on upgrading process technology, pilot plant research, Zenith fosters a culture of innovation, driven by continuous and new product development with physical and metallurgical customer interactions,
Slide 20: Driving market presence with dynamic distribution and sales network
Driving market presence with dynamic distribution and sales network 50+ leverages a robust distribution3000+ Zenith network of Core Focus: Zenith excels in marketing branded generic drugs, a significant Distributors Stockists business driver. • Nationwide presence ensures products are easily accessi
Slide 21: Strategic government engagements for healthcare advancements
Strategic government engagements for healthcare advancements Current Govt Tenders: Actively engaged in government tenders, collaborating with major state and central institutions for crucial healthcare initiatives 01 Proposal Submission Initiate the process by • Madhya Pradesh Public Health Services
Slide 22: Strategic alliances and collaborations
Strategic alliances and collaborations 50+ Contract Manufacturing Partners Other strategic partnership Manufacture Products bearing Technical & Marketing Agreement Medizone Healthcare Limited Trademark of Ajanta Limited for Contract Manufacturing Distribution Agreement Ramky Enviro Engineers Limited
Slide 23: Certifications to our credibility
Certifications to our credibility WHO GMP complaint LMHRA certification GLP Certificate ISO 9001:2015 certified Committed to regulatory compliance ensuring high standards and credibility in every product
Slide 24: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 25: Profit and Loss (in INR Lakhs)
Profit and Loss (in INR Lakhs) Particulars FY2020-21 FY2021-22 FY2022-23 SEP 2023 Standalone Consolidated Consolidated Consolidated Revenue From Operations 7340 9166 11452 6941 Cost of Materials and Change in 5201 7260 8518 4570 Inventories Gross Profit 2140 1906 2934 2371 Employee Benefit Expenses
Slide 26: Balance Sheet (in INR Lakhs)
Balance Sheet- (in INR Lakhs) Particulars FY2020-21 FY2021-22 FY2022-23 As on-SEP 2023 EQUITY AND LIABILITIES Standalone Consolidated Consolidated Consolidated Share Capital 40 40 40 1200 Reserves and Surplus 855 1169 1684 1065 Total Shareholders Funds 895 1209 1724 2265 Minority Interest 1 1 1 - Lo
Slide 27: Balance Sheet (in INR Lakhs)
Balance Sheet- (in INR Lakhs) Particulars FY2020-21 FY2021-22 FY2022-23 As on-SEP 2023 Standalone Consolidated Consolidated Consolidated Property, Plant & Equipment & Intangible Assets i) Property, Plant & Equipment 922 1047 1173 1094 ii) Capital Work-in-progress - 266 - 89 iii) Tangible Assets - -
Slide 28: Financial Metrics
Financial Metrics: 14000 40% 35% 34% 12000 11452 30% 29% 10000 9166 26% 25% 8000 7340 21% 6941 20% 6000 15% 14% 4000 11% 2934 10% 10% 8% 8% 2140 2371 7% 1906 6% 6% 2000 4% 5% 4% 967 962 5% 3% 703 683 721 759 540 460 441 303 313 515 0 Revenue From Gross Profit EBITDA Profit Before Tax Profit After Ta
Slide 29: Contact us
Contact us Registered office: K. No. 72/5, Village Muradpura Depalpur, Near Kalaria, Indore, Madhya Pradesh Pin: 453001 INDIA Email: marketing@zenithdrugs.com Phone: +91-9285106855